Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of Agrippal S1 2007-2008 influenza vaccine in adults and elderly subjects
2007-000963-28Phase 2Completed
- Sponsor
- Novartis
- Start
- Jun 2007
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of influenza vaccine, inactivated, surface antigen in influenza (2 arms), sponsored by Novartis. Primary endpoints: Immunogenicity by single radial hemolysis at day 21, EU immunogenicity criteria in non-elderly adults and 2 more. Started Jun 2007; status: completed.
02
Drugs
influenza vaccine, inactivated, surface antigen
03
Conditions
influenza
Beyond the preview
Go deeper on 2007-000963-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-000963-28.